$APUS

Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlem

MindWave Innovations, a subsidiary of Apimeds Pharmaceuticals (NYSE: APUS), signed three agreements to build and operate blockchain networks for AQUAE, Flash Sports & Media (FLZH), and BlockAssure. The networks will operate on MindChain and MindWave will earn fees, equity, or token allocations. APUS previously disclosed substantial doubt about its ability to continue as a going concern.

MindWave Innovations (APUS) signed a 2-year agreement with BlockAssure to build and operate AssureChain, an insurance and reinsurance network on MindChain. MindWave will earn development fees and receive 20% of AssureCoin's total supply. The agreement took effect on Oct. 4, 2026, and includes automatic renewal clauses.

Apimeds Pharmaceuticals US (APUS) appointed Eric Sherb as CFO on October 1, 2026, following Erick Frim's resignation as Interim CFO on September 29, 2026. Sherb has 18+ years of capital markets experience and is a Certified Public Accountant. Frim's departure was not due to any disagreement with the company.

Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc.,

Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure Agreement strengthens MindWave’s position as a technology provider for ecosystem finance and environmental markets MATAWAN, New Jersey — September 24, 2026 — MindWave Innovation

Meta (META) rose 4.5% to $777.59, driven by AI strategy. Everpure (P) surged 11.15% to $121.88, reaffirming fiscal 2027 guidance. Akamai (AKAM) fell 6.78% to $110.41, then jumped 20.65% after-hours on a $11.6B AI deal. Apimeds (APUS) soared 114.85% to $4.92 on a blockchain agreement. Costco (COST) dipped 0.91% to $896.48 despite beating Q4 estimates.

Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.

Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company, Erik Emerson, Lokahi Therapeutic

Apimeds Pharmaceuticals US, Inc. (APUS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “ Assignment Agreement ”) with FreeT Inc., a comp